Luneri

NAD+ clinical brief

NAD+

Dossier liveB

Compound

CompoundStructured dossier pageDossier-backedDietary Supplement

Compare alternatives Build protocol How this page is sourced

Evidence strength

High confidence

5 meta-analyses with 59 RCTs with 93 tracked studies

Evidence index74/100

Dossier-backed

This page is grounded in structured dossier fields, with deterministic summaries layered on top for readability.

What it is for

NAD+ repletion - low-dose initiation or cost-sensitive protocol

The clearest current human use case based on dose, outcomes, and clinical coverage.

What moves

Human linked

Highest-signal biomarkers

Nad Blood

Clinical response

Increase

Grade A

Nad Whole Blood

Clinical response

Increase

Grade A

MMA

Methylation

Decrease

Grade A

Safety context

Safety gateReview before protocol

Lead safety constraint

Protocol cautionC

Drug interaction

Both metformin (via AMPK activation through complex I inhibition) and NAD+ precursors (via SIRT1/AMPK cross-talk) activate overlapping metabolic pathways.

Dossier-backed

Evidence index

Promoted product-registry confidence score

Meta-analyses

Pooled human evidence

RCTs

Randomized clinical trials

Tracked studies

Studies currently mapped to this dossier

Free previewDossier openingDerived

Preview summary

Clinical opening brief

How this is sourcedDerived

This executive summary is generated by application logic from structured dossier evidence and safety fields.

NAD+ is a compound with its clearest current use in NAD+ repletion - low-dose initiation or cost-sensitive protocol.

High confidence human evidence supports the brief, anchored by 93 tracked studies, 5 meta-analyses, 59 RCTs and the most reliable movement in Nad Blood, Nad Whole Blood, MMA.

Both metformin (via AMPK activation through complex I inhibition) and NAD+ precursors (via SIRT1/AMPK cross-talk) activate overlapping metabolic pathways. Both metformin (via AMPK activation through complex I inhibition) and NAD+ precursors (via SIRT1/AMPK cross-talk) activate overlapping metabolic pathways. Do not assume NR improves metabolic parameters in overweight adults; monitor fasting glucose and insulin in long-term users

Free dossier previewResearch access

Research unlocks the working sections of the brief

The clinical opening stays public. Research opens the deeper evidence, biomarker, dosing, and PGx layers once you want the full operating brief.

Overview

Mechanism, safety, and scope

The opening memo leads into the working sections where the compound gets pressure-tested before it belongs in a real protocol.

Mechanism summary, safety framing, and evidence-scope caveats continue here.

Synergies, contradictions, and unresolved questions sit alongside the overview before the tables begin.

Reading path

From memo into tables

Evidence rows show trial design, outcome direction, grading, and the specific claims that survived synthesis.

Biomarker groups, dosing protocols, and PGx notes sit behind the next layer once you need operational detail.

Evidence

Graded study rows

Trial design, endpoint direction, and confidence cues.

Biomarkers

Grouped outcome maps

Human-linked markers, dosing context, and cluster summaries.

Dosing

Protocol context

Use-case-specific doses, duration, and practical notes.

PGx

Actionable modifiers

Genes, interactions, and what actually changes practice.

Biomarker and evidence layer

Highest-signal biomarkers, evidence rows, and claim-by-claim grading live here once the dossier graduates from opening memo to working brief.

Current public view: Dossier live. Full access reveals the actual operating tables.

Protocol detail

Dosing schedules, form choices, and practical timing are held back until the compound is worth operationalizing.

PGx modifiers and safety friction stay in the same layer so the protocol decision is made in one pass, not by guesswork.

Research unlockPreview

Evidence, biomarkers, dosing, and PGx stay behind the glass

You are already inside the dossier. Upgrade when you need the full working sections instead of only the opening memo.